Partially HLA-matched Virus Specific T cell therapy (Baylor College of Medicine)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePartially HLA-matched Virus Specific T cell therapy (Baylor College of Medicine)
Drug Alias NameBanked Anti-SARS Cov-2 T Cell
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Virus Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaylor College Of Medicine
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Virus Diseases

Other Information

ATC CodeN/A
Related LinksN/A